tailieunhanh - báo cáo hóa học:" A brief symptom index for advanced renal cell carcinoma"

Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí hóa học đề tài : A brief symptom index for advanced renal cell carcinoma | BioMed Central Health and Quality of Life Outcomes Open Access A brief symptom index for advanced renal cell carcinoma David T Eton 1 2 David Cella1 2 Jennifer Bacik3 and Robert J Motzer4 Address 1Center on Outcomes Research and Education Evanston Northwestern Healthcare 1001 University Place Suite 100 Evanston IL 60201 USA 2Northwestern University Feinberg School of Medicine Chicago IL USA 3Department of Epidemiology and Biostatistics Memorial Sloan-Kettering Cancer Center New York NY USA and 4Genitourinary Oncology Service Division of Solid Tumor Oncology Memorial Sloan-Kettering Cancer Center New York NY USA Email David T Eton - d-eton@ David Cella - d-cella@ Jennifer Bacik - bacik1@ Robert J Motzer - motzerr@ Corresponding author Published 26 September 2006 Received 28 June 2006 Acce ted 26 Setember 2006 Health and Quality of Life Outcomes 2006 4 68 doi 1477-7525-4-68 p p This article is available from http content 4 1 68 2006 Eton et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract__ Background Our objective was to test a brief symptom index for advanced renal cell carcinoma a disease affecting over 38 000 Americans each year and often diagnosed in late stages. Methods We conducted secondary data analyses on patient-reported outcomes of 209 metastatic renal cell carcinoma patients participating in a Phase III clinical trial. Patient-reported outcomes obtained from the FACT-Biological Response Modifier FACT-BRM scale were available at baseline 2 and 8 weeks. We analyzed data from eight FACT-BRM items previously identified by clinical experts to represent the most